Huge win for Starpharma with A$5.5m R&D refund – groundbreaking drugs on the way?
Starpharma Holdings Limited, an Australian biotechnology company known for its work in dendrimer technology, has secured an AU$5.5 million Research and Development (R&D) Tax Incentive refund for the financial year 2024. This refund is due to the company’s qualifying R&D activities across its innovative product portfolio, including its DEP drug delivery programs and the antiviral […]